ALERTNESS AID- caffeine tablet Chain Drug Consortium

Premier Value 44-226

Active ingredient (in each tablet)

Caffeine 200 mg

Purpose

Alertness aid

Use

helps restore mental alertness or wakefulness when experiencing fatigue or drowsiness

Warnings

For occasional use only

Caffeine warning: The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.

Do not use

- for children under 12 years of age
- as a substitute for sleep

Stop use and ask a doctor if

fatigue or drowsiness persists or continues to recur.

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- adults and children 12 years and over: take 1 tablet not more often than every 3 to 4 hours
- children under 12 years: do not use

Other information

- each tablet contains: calcium 35 mg
- TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN
- store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F)
- see end flap for expiration date and lot number

Inactive ingredients

corn starch, D&C yellow #10 aluminum lake, dextrates hydrated, dibasic calcium phosphate dihydrate, FD&C yellow #6 aluminum lake, magnesium stearate, microcrystalline cellulose, silicon dioxide

Questions or comments?

1-800-426-9391

Principal Display Panel

Premier Value®

*COMPARE TO THE ACTIVE INGREDIENT IN VIVARIN®

Alertness Aid

Caffeine 200 mg
ALERTNESS AID

Equal to about a cup of coffee

40 Tablets

actual size

INDEPENDENTLY TESTED

PV

SATISFACTION GUARANTEED

TAMPER EVIDENT: DO NOT USE IF PACKAGE IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING

*This product is not manufactured or distributed by Meda AB, owner of the registered trademark Vivarin®. 50844 REV1219A22610

Distributed By: Pharmacy Value Alliance, LLC 407 East Lancaster Avenue, Wayne, PA 19087

If for any reason you are not satisfied with

this product, please return it to the store where purchased for a full refund.



ALERTNESS AID

caffeine tablet

Product Information

Product Type HUMAN OTC DRUG Item Code (Source) NDC:68016-680

ORAL **Route of Administration**

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength

CAFFEINE (UNII: 3G6A5W338E) (CAFFEINE - UNII:3G6A5W338E) **CAFFEINE** 200 mg

Inactive Ingredients

Ingredient Name	Strength
STARCH, CORN (UNII: O8232NY3SJ)	
D&C YELLOW NO. 10 ALUMINUM LAKE (UNII: CQ3XH3DET6)	
DEXTROSE MONOHYDRATE (UNII: LX22YL083G)	
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)	

FD&C YELLOW NO. 6 (UNII: H77VEI93A8) MAGNESIUM STEARATE (UNII: 70097M6I30)

MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)

SILICON DIOXIDE (UNII: ETJ7Z6XBU4)

Product Characteristics

Color	yellow	Score	no score
Shape	ROUND	Size	11mm
Flavor		Imprint Code	44;226
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68016-680- 40	5 in 1 CARTON	11/21/1996	
1		8 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:68016-680- 16	2 in 1 CARTON	11/21/1996	05/17/2023
2		8 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Application Number or Monograph Marketing Start Marketing End Marketing

Category	Citation	Date	Date
OTC Monograph Drug	M011	11/21/1996	

Labeler - Chain Drug Consortium (101668460)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		038154464	pack(68016-680)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		832867837	manufacture(68016-680) , pack(68016-680)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		967626305	pack(68016-680)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		117025878	manufacture(68016-680)

Revised: 3/2023 Chain Drug Consortium